{"id":"tofa","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Generic Available","category":"availability"},{"label":"LOE Approaching","category":"status"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Overall Infections","drugRate":"20%","severity":"common","organSystem":""},{"effect":"Upper Respiratory Tract Infections","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Nasopharyngitis","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Urinary Tract Infections","drugRate":"2%","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Serious Infections","drugRate":"1.7%","severity":"serious"}]},"trials":[],"aliases":[],"patents":[{"applNo":"N208246","source":"FDA Orange Book","status":"Active","expires":"Mar 14, 2034","useCode":"U-3326","territory":"US","drugProduct":false,"patentNumber":"11253523","drugSubstance":false},{"applNo":"N208246","source":"FDA Orange Book","status":"Expired","expires":"Dec 8, 2025","useCode":"","territory":"US","drugProduct":false,"patentNumber":"RE41783","drugSubstance":true},{"applNo":"N208246","source":"FDA Orange Book","status":"Active","expires":"Mar 14, 2034","useCode":"","territory":"US","drugProduct":true,"patentNumber":"9937181","drugSubstance":false},{"applNo":"N208246","source":"FDA Orange Book","status":"Active","expires":"Mar 14, 2034","useCode":"","territory":"US","drugProduct":true,"patentNumber":"10639309","drugSubstance":false},{"applNo":"N208246","source":"FDA Orange Book","status":"Active","expires":"Jun 8, 2026","useCode":"","territory":"US","drugProduct":false,"patentNumber":"RE41783*PED","drugSubstance":false},{"applNo":"N208246","source":"FDA Orange Book","status":"Active","expires":"Sep 14, 2034","useCode":"","territory":"US","drugProduct":false,"patentNumber":"9937181*PED","drugSubstance":false},{"applNo":"N208246","source":"FDA Orange Book","status":"Active","expires":"Sep 14, 2034","useCode":"","territory":"US","drugProduct":false,"patentNumber":"10639309*PED","drugSubstance":false},{"applNo":"N208246","source":"FDA Orange Book","status":"Active","expires":"Sep 14, 2034","useCode":"","territory":"US","drugProduct":false,"patentNumber":"11253523*PED","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=TOFA","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:58:22.610322+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:58:22.610185+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:58:27.791138+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TOFA","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:58:28.165844+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1562779/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:58:28.866962+00:00"}},"allNames":["tofa"],"offLabel":[],"synonyms":[],"timeline":[{"date":"2018-05-30","type":"positive","source":"FDA Orange Book","milestone":"Xeljanz approved — EQ 10MG BASE"},{"date":"2020-09-25","type":"positive","source":"FDA Orange Book","milestone":"Xeljanz approved — EQ 1MG BASE/ML"},{"date":"2021-08-19","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 2 manufacturers approved"},{"date":"2025-12-08","type":"negative","source":"FDA Orange Book","milestone":"Substance patent RE41783 expires"}],"approvals":[],"ecosystem":[],"mechanism":{"target":"Aurora kinase B, BMP-2-inducible protein kinase, Calcium/calmodulin-dependent protein kinase type 1","modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Tofa's mechanism of action is not well-documented, but it is believed to involve interaction with a specific protein or receptor in the body."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=tofa","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tofa","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-31T10:35:28.013283","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:58:30.511624+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"tofa","indications":{"approved":[{"name":"Juvenile idiopathic arthritis, extended oligoarthritis","diseaseId":"juvenile-idiopathic-arthritis-extended-oligoarthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Juvenile psoriatic arthritis","diseaseId":"juvenile-psoriatic-arthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Polyarticular juvenile idiopathic arthritis","diseaseId":"polyarticular-juvenile-idiopathic-arthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Psoriatic arthritis","diseaseId":"psoriatic-arthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rheumatoid arthritis","diseaseId":"rheumatoid-arthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Ulcerative colitis","diseaseId":"ulcerative-colitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"currentOwner":"Pfizer","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07406204","phase":"PHASE4","title":"Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)","status":"NOT_YET_RECRUITING","sponsor":"Hayat Abad Medical Complex, Peshawar","startDate":"2026-02-15","conditions":["Alopecia Areata","Alopecia Totalis (AT)","Alopecia Universalis"],"enrollment":78,"completionDate":"2026-08-15"},{"nctId":"NCT04485325","phase":"PHASE4","title":"Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA Patients","status":"COMPLETED","sponsor":"Dr. Frank Behrens","startDate":"2019-11-04","conditions":["Rheumatic Arthritis"],"enrollment":92,"completionDate":"2024-03-31"},{"nctId":"NCT05133297","phase":"PHASE2","title":"The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2022-02-16","conditions":["Rheumatoid Arthritis"],"enrollment":101,"completionDate":"2023-05-30"},{"nctId":"NCT05577962","phase":"NA","title":"Opioid Free Anesthesia on the Quality of Early Recovery","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2023-02-01","conditions":["Opioid-free Anesthesia"],"enrollment":160,"completionDate":"2023-12-31"},{"nctId":"NCT05431283","phase":"","title":"Real-world Effectiveness of Tofacitinib on Ulcerative Colitis Associated Spondyloarthropathy","status":"UNKNOWN","sponsor":"Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)","startDate":"2022-04-25","conditions":["Ulcerative Colitis","Spondyloarthropathy"],"enrollment":100,"completionDate":"2023-12-31"},{"nctId":"NCT03755466","phase":"PHASE2","title":"Examination of Efficacy and Safety of Baricitinib in RA Patients","status":"UNKNOWN","sponsor":"Shinshu University","startDate":"2018-11-21","conditions":["Rheumatoid Arthritis"],"enrollment":90,"completionDate":"2025-11-20"},{"nctId":"NCT03580343","phase":"PHASE2","title":"Tofacitinib for Inflammatory Eye Disease","status":"UNKNOWN","sponsor":"Washington University School of Medicine","startDate":"2019-04-04","conditions":["Uveitis","Scleritis"],"enrollment":5,"completionDate":"2021-04-04"},{"nctId":"NCT01741493","phase":"PHASE1","title":"A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-11","conditions":["Rheumatoid Arthritis"],"enrollment":67,"completionDate":"2013-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"_patentsChecked":true,"crossReferences":{"chemblId":"CHEMBL1562779","pubchemSID":"24714898"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Pfizer","relationship":"Current Owner"}],"publicationCount":192,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturers":8,"_genericFilersChecked":true,"genericManufacturerList":["Ajanta Pharma Ltd","Aurobindo Pharma Ltd","Biocon Pharma","Dexcel","Hikma","Micro Labs","Sinotherapeutics Inc","Zydus Pharms"],"status":"active","brandName":"TOFA","companyName":"Pfizer","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":4,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:58:30.511624+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}